Radiation after triple therapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding radiation therapy after a combination of three treatments (like immunotherapy and targeted therapy) can help people with liver cancer that cannot be surgically removed. It may be a good option if your tumor responded to the triple therapy but you still cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have liver cancer that cannot be removed by surgery
- You have received a combination of three treatments (called 'triple therapy') and your tumor either shrank or stayed the same, but you still cannot have surgery
- Your liver function is fairly good (Child-Pugh class A or B)
- You are physically active enough to do daily tasks (ECOG score 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
This trial tests a combination of three treatments for a specific type of aggressive liver cancer called infiltrative hepatocellular carcinoma (HCC). It combines targeted therapy (lenvatinib), immunotherapy (sintilimab), and a procedure that delivers chemotherapy directly to the liver (bTAE-HAIC). The goal is to see if this triple approach works better for people with large tumors or those that have spread to the portal vein.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.